Using intranasal dexmedetomidine to reduce anxiety and depression in colorectal cancer patients during surgery
Clinical Study of Dexmedetomidine Administered Intranasally to Relieve Perioperative Anxiety and Depression in Patients With Colorectal Tumors
PHASE3 · First Affiliated Hospital of Chongqing Medical University · NCT06139926
This study is testing if a nasal spray of dexmedetomidine can help reduce anxiety and depression in colorectal cancer patients during their first surgery.
Quick facts
| Phase | PHASE3 |
|---|---|
| Study type | Interventional |
| Enrollment | 126 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | First Affiliated Hospital of Chongqing Medical University (other) |
| Locations | 1 site (Chongqing, Chongqing) |
| Trial ID | NCT06139926 on ClinicalTrials.gov |
What this trial studies
This clinical study investigates the effects of intranasally administered dexmedetomidine on relieving perioperative anxiety and depression in patients diagnosed with colorectal cancer who are undergoing their first oncologic procedure. The study aims to address the growing prevalence of anxiety and depression among oncology patients, particularly as these conditions can complicate their prognosis. By focusing on a novel administration route, the research seeks to provide a practical and clinically significant intervention for improving patient outcomes during surgery.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with a preoperative diagnosis of colorectal cancer who are scheduled for their first oncologic procedure under general anesthesia.
Not a fit: Patients with diagnosed mental illnesses, cognitive impairments, or those on certain psychiatric medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly alleviate anxiety and depression in colorectal cancer patients, enhancing their overall surgical experience and recovery.
How similar studies have performed: While there has been limited research on the use of dexmedetomidine for anxiety and depression in oncology patients, similar approaches in other contexts have shown promise, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients with a preoperative diagnosis of colorectal cancer who were to undergo their first oncologic procedure 2. Patients who opted for general anesthesia via orotracheal intubation 3. Age ≥18 years old 4. ASA classification II-III (5) 18.0 \< BMI \< 30.0 5. Signed informed consent. Exclusion Criteria: 1. Diagnosed mental illness or cognitive impairment, or taking antipsychotic, sedative-hypnotic, or anxiolytic-depressant medications 2. Serious abnormalities of liver or kidney function. 3. Prior alcohol or drug abuse 4. Second or third degree atrioventricular block, severe sinus bradycardia (\<50 beats/min), sick sinus node syndrome, congenital heart disease, and other cardiac arrhythmias that severely affect hemodynamic stability 5. Grade 3 hypertension 6. Any disease of the head, such as cerebral infarcts, epilepsy, head trauma, etc. 7. Confirmed diagnosis of non-tumor-induced chronic ( ≥3 months) neuropathic pain 8. Inability to understand the meaning of the scale and complete the scoring. 9. Women preparing for pregnancy, pregnant women, or breastfeeding 10. Patients with myasthenia gravis 11. Respiratory function score ≥3
Where this trial is running
Chongqing, Chongqing
- The First Affiliated Hospital of Chongqing Medical University — Chongqing, Chongqing, China (RECRUITING)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Colorectal Cancer